 Fab fragment of sifalimumab bound to IFN-α2A. FromPDB:4ypg. | |
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | Interferon α |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6518H10008N1724O2032S38 |
| Molar mass | 146252.08 g·mol−1 |
 N Y (what is this?) (verify) | |
Sifalimumab is a human monoclonal antibody designed for the treatment ofSLE,dermatomyositis, andpolymyositis.[1] It targets interferon a.[2]
Sifalimumab was developed byMedImmune; as of 2017 development had been terminated in favor of moving a competing internal product,anifrolumab, into Phase III trials.[3][4][5]
 | Thismonoclonal antibody–related article is astub. You can help Wikipedia byexpanding it. |
 | Thisantineoplastic orimmunomodulatorydrug article is astub. You can help Wikipedia byexpanding it. |
